



OPEN ACCESS

EDITED AND REVIEWED BY
Maria Angela Sortino,
University of Catania, Italy

*CORRESPONDENCE
Jin Chen,
✉ 470816153@qq.com

RECEIVED 18 July 2024
ACCEPTED 09 September 2024
PUBLISHED 20 September 2024

CITATION

Lv Y, Chen J, Hu J, Qian Y, Kong Y and Fu L (2024) Corrigendum: Nonmuscle myosin heavy chain IIA-mediated exosome release via regulation of the rho-associated kinase 1/myosin light chains/actin pathway. *Front. Pharmacol.* 15:1465932. doi: 10.3389/fphar.2024.1465932

COPYRIGHT

© 2024 Lv, Chen, Hu, Qian, Kong and Fu. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Nonmuscle myosin heavy chain IIA-mediated exosome release via regulation of the rho-associated kinase 1/myosin light chains/actin pathway

Yanni Lv¹, Jin Chen^{2*}, Jinfang Hu¹, Yisong Qian³, Ying Kong¹ and Longsheng Fu¹

¹Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Jiangxi, China, ²Department of Neurology, The First Affiliated Hospital of Nanchang University, Jiangxi, China, ³Institute of Translational Medicine, Nanchang University, Nanchang, China

KEYWORDS

nonmuscle myosin heavy chain IIA, exosome release, rho-associated kinase 1/myosin light chains/actin, microglial cells, lipopolysaccharide

A Corrigendum on Nonmuscle myosin heavy chain IIA-mediated exosome release via regulation of the rho-associated kinase 1/myosin light chains/actin pathway

by Lv Y, Chen J, Hu J, Qian Y, Kong Y and Fu L (2020). *Front. Pharmacol.* 11:598592. doi: 10.3389/fphar.2020.598592

In the published article, there was an error in [Figure 2](#) as published. In [Figure 2B](#), the panel representing CD18 in the LPS+blebbistatin group was a repeat of the panel representing CD9 in the LPS+blebbistatin group. The corrected [Figure 2](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 2

The myosin inhibitor, blebbistatin, inhibited exosome release from microglial cells under the stimulation of LPS. The extracted exosomes were divided into those extracted from control microglial cells, microglial cells incubated with 1 mg/mL LPS for 24 h, and microglial cells added with 1 μ M blebbistatin 0.5 h before the 24 h stimulation of LPS. **(A)** Nanoparticle tracking analysis for the concentration of exosomes. **(B)** Flow cytometry analysis for CD9-labeled positive rate, CD81-labeled positive rate, or control FITC-IgG-labeled positive rate. **(C)** The protein expression levels of CD9 and CD81 exosome marker proteins were examined by Western blot. Western blots were quantified. Nine independent experiments were analyzed. A histogram depicts the quantitative representation of CD9 and CD81 protein expression for each group. The data were averages \pm SD, n = 9. **p < 0.01 vs. control microglial cells; ##p < 0.01 vs. microglial cells stimulated with LPS.